Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma

Sarah T. Wilkinson, Kristie A. Vanpatten, Diane R. Fernandez, Patrick Brunhoeber, Karl E. Garsha, Betty J. Glinsmann-Gibson, Thomas M. Grogan, Julie Teruya-Feldstein, Lisa M Rimsza

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Loss of major histocompatibility complex class II (MHC II) expression is associated with poor patient outcome in diffuse large B-cell lymphoma (DLBCL). As MHC II molecules are lost with plasmacytic differentiation in normal cells, we asked whether MHC II loss in DLBCL is associated with an altered differentiation state. We used gene expression profiling, quantum dots, and immunohistochemistry to study the relationship between MHC II and plasma cell markers in DLBCL and plasmablastic lymphoma (PBL). Results demonstrate that MHC II(-) DLBCL immunophenotypically overlap with PBL and demonstrate an inverse correlation between MHC II and plasma cell markers MUM1, PRDM1/Blimp1, and XBP1s. In addition, MHC II expression is significantly higher in germinal center-DLBCL than activated B cell-DLBCL. A minor subset of cases with an unusual pattern of mislocalized punctate MHC II staining and intermediate levels of mRNA is also described. Finally, we show that PBL is negative for MHC II. The results imply a spectrum of MHC II expression that is more frequently diminished in tumors derived from B cells at the later stages of differentiation (with complete loss in PBL). Our observations provide a possible unifying concept that may contribute to the poor outcome reported in all MHC II(-) B-cell tumors.

Original languageEnglish (US)
Pages (from-to)1459-1467
Number of pages9
JournalBlood
Volume119
Issue number6
DOIs
StatePublished - Feb 9 2012

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Plasma Cells
Major Histocompatibility Complex
Cell Differentiation
Cells
Plasmas
Tumors
Gene expression
Semiconductor quantum dots
B-Lymphocytes
B-Cell Lymphoma
Messenger RNA
Molecules
Quantum Dots
Germinal Center
Gene Expression Profiling
Neoplasms
Immunohistochemistry
Staining and Labeling

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. / Wilkinson, Sarah T.; Vanpatten, Kristie A.; Fernandez, Diane R.; Brunhoeber, Patrick; Garsha, Karl E.; Glinsmann-Gibson, Betty J.; Grogan, Thomas M.; Teruya-Feldstein, Julie; Rimsza, Lisa M.

In: Blood, Vol. 119, No. 6, 09.02.2012, p. 1459-1467.

Research output: Contribution to journalArticle

Wilkinson, ST, Vanpatten, KA, Fernandez, DR, Brunhoeber, P, Garsha, KE, Glinsmann-Gibson, BJ, Grogan, TM, Teruya-Feldstein, J & Rimsza, LM 2012, 'Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma', Blood, vol. 119, no. 6, pp. 1459-1467. https://doi.org/10.1182/blood-2011-07-363820
Wilkinson, Sarah T. ; Vanpatten, Kristie A. ; Fernandez, Diane R. ; Brunhoeber, Patrick ; Garsha, Karl E. ; Glinsmann-Gibson, Betty J. ; Grogan, Thomas M. ; Teruya-Feldstein, Julie ; Rimsza, Lisa M. / Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. In: Blood. 2012 ; Vol. 119, No. 6. pp. 1459-1467.
@article{9762106868b745df9090689ee1afb663,
title = "Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma",
abstract = "Loss of major histocompatibility complex class II (MHC II) expression is associated with poor patient outcome in diffuse large B-cell lymphoma (DLBCL). As MHC II molecules are lost with plasmacytic differentiation in normal cells, we asked whether MHC II loss in DLBCL is associated with an altered differentiation state. We used gene expression profiling, quantum dots, and immunohistochemistry to study the relationship between MHC II and plasma cell markers in DLBCL and plasmablastic lymphoma (PBL). Results demonstrate that MHC II(-) DLBCL immunophenotypically overlap with PBL and demonstrate an inverse correlation between MHC II and plasma cell markers MUM1, PRDM1/Blimp1, and XBP1s. In addition, MHC II expression is significantly higher in germinal center-DLBCL than activated B cell-DLBCL. A minor subset of cases with an unusual pattern of mislocalized punctate MHC II staining and intermediate levels of mRNA is also described. Finally, we show that PBL is negative for MHC II. The results imply a spectrum of MHC II expression that is more frequently diminished in tumors derived from B cells at the later stages of differentiation (with complete loss in PBL). Our observations provide a possible unifying concept that may contribute to the poor outcome reported in all MHC II(-) B-cell tumors.",
author = "Wilkinson, {Sarah T.} and Vanpatten, {Kristie A.} and Fernandez, {Diane R.} and Patrick Brunhoeber and Garsha, {Karl E.} and Glinsmann-Gibson, {Betty J.} and Grogan, {Thomas M.} and Julie Teruya-Feldstein and Rimsza, {Lisa M}",
year = "2012",
month = "2",
day = "9",
doi = "10.1182/blood-2011-07-363820",
language = "English (US)",
volume = "119",
pages = "1459--1467",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma

AU - Wilkinson, Sarah T.

AU - Vanpatten, Kristie A.

AU - Fernandez, Diane R.

AU - Brunhoeber, Patrick

AU - Garsha, Karl E.

AU - Glinsmann-Gibson, Betty J.

AU - Grogan, Thomas M.

AU - Teruya-Feldstein, Julie

AU - Rimsza, Lisa M

PY - 2012/2/9

Y1 - 2012/2/9

N2 - Loss of major histocompatibility complex class II (MHC II) expression is associated with poor patient outcome in diffuse large B-cell lymphoma (DLBCL). As MHC II molecules are lost with plasmacytic differentiation in normal cells, we asked whether MHC II loss in DLBCL is associated with an altered differentiation state. We used gene expression profiling, quantum dots, and immunohistochemistry to study the relationship between MHC II and plasma cell markers in DLBCL and plasmablastic lymphoma (PBL). Results demonstrate that MHC II(-) DLBCL immunophenotypically overlap with PBL and demonstrate an inverse correlation between MHC II and plasma cell markers MUM1, PRDM1/Blimp1, and XBP1s. In addition, MHC II expression is significantly higher in germinal center-DLBCL than activated B cell-DLBCL. A minor subset of cases with an unusual pattern of mislocalized punctate MHC II staining and intermediate levels of mRNA is also described. Finally, we show that PBL is negative for MHC II. The results imply a spectrum of MHC II expression that is more frequently diminished in tumors derived from B cells at the later stages of differentiation (with complete loss in PBL). Our observations provide a possible unifying concept that may contribute to the poor outcome reported in all MHC II(-) B-cell tumors.

AB - Loss of major histocompatibility complex class II (MHC II) expression is associated with poor patient outcome in diffuse large B-cell lymphoma (DLBCL). As MHC II molecules are lost with plasmacytic differentiation in normal cells, we asked whether MHC II loss in DLBCL is associated with an altered differentiation state. We used gene expression profiling, quantum dots, and immunohistochemistry to study the relationship between MHC II and plasma cell markers in DLBCL and plasmablastic lymphoma (PBL). Results demonstrate that MHC II(-) DLBCL immunophenotypically overlap with PBL and demonstrate an inverse correlation between MHC II and plasma cell markers MUM1, PRDM1/Blimp1, and XBP1s. In addition, MHC II expression is significantly higher in germinal center-DLBCL than activated B cell-DLBCL. A minor subset of cases with an unusual pattern of mislocalized punctate MHC II staining and intermediate levels of mRNA is also described. Finally, we show that PBL is negative for MHC II. The results imply a spectrum of MHC II expression that is more frequently diminished in tumors derived from B cells at the later stages of differentiation (with complete loss in PBL). Our observations provide a possible unifying concept that may contribute to the poor outcome reported in all MHC II(-) B-cell tumors.

UR - http://www.scopus.com/inward/record.url?scp=84856882081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856882081&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-07-363820

DO - 10.1182/blood-2011-07-363820

M3 - Article

C2 - 22167754

AN - SCOPUS:84856882081

VL - 119

SP - 1459

EP - 1467

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -